$MDCO (The Medicines Company)

$MDCO {{ '2016-01-11T15:29:19+0000' | timeago}} • Announcement

Biopharmaceutical company $MDCO said it has begun enrolling patients in the ORION-1 Phase 2 study to compare the effect of different doses of ALN-PCSsc given as subcutaneous injections in a quarterly or bi-annual dosing regimen in subjects with atherosclerotic cardiovascular disease (ASCVD) or risk equivalent ASCVD and elevated LDL-C.

$MDCO {{ '2017-03-31T12:13:59+0000' | timeago}} • Announcement

$MDCO has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will stand for election at the company’s 2017 Annual Meeting of Stockholders.

$MDCO {{ '2017-02-28T12:55:08+0000' | timeago}} • Announcement

$MDCO's revenue for 4Q16 dropped to $25.2MM from $67.2MM last year. Included in revenue for 4Q16 was $9.1MM of royalty revenues derived from the gross profit on authorized generic sales of Angiomax (bivalirudin) by Sandoz, Inc. Worldwide Angiomax/Angiox (bivalirudin) net product sales fell to $7.8MM from $23.2MM.

$MDCO {{ '2017-02-28T12:54:45+0000' | timeago}} • Announcement

$MDCO reported a wider 4Q16 loss from continuing operations due to lower revenue. Loss from continuing operations widened to $124.43MM or $1.77 per share from $68.24MM or $0.99 per share last year. Adjusted loss per share widened to $1.19 from $0.86.

$MDCO {{ '2016-09-21T12:38:06+0000' | timeago}} • Announcement

$MDCO said the initial $32MM award will support a Phase IIIb trial of its investigational antibiotic, Carbavance, for treatment of gram-negative infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

$MDCO {{ '2016-09-21T12:37:05+0000' | timeago}} • Announcement

$MDCO said Biomedical Advanced Research and Development Authority (BARDA) will provide $32MM in initial funding, and up to an additional $100MM over about 5 years if all options to extend partnership are exercised by BARDA.

$MDCO {{ '2016-09-21T12:35:47+0000' | timeago}} • Announcement

$MDCO entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA). The partnership was established under U.S. Department of Health and Human Services' (HHS) Other Transactional Authority (OTA) and is a distinctive, flexible, portfolio-based approach to funding drug development.

$MDCO {{ '2016-09-21T12:34:51+0000' | timeago}} • Announcement

$MDCO received up to $132MM to develop portfolio of new antibiotics targeting drug-resistant gram-negative infections under strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA).

$MDCO {{ '2016-08-31T15:14:41+0000' | timeago}} • Announcement

$MDCO said it provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).

$MDCO {{ '2016-06-27T14:35:50+0000' | timeago}} • Announcement

$MDCO said it expects a reduction in annual selling, general and administrative and related research and development expenses of between $65MM and $80MM. After closing this deal, $MDCO will have executed two transactions with the potential to generate up to $1.2Bil in non-dilutive cash.

$MDCO {{ '2016-06-27T14:31:14+0000' | timeago}} • Announcement

$MDCO said it closed divestiture of its non-core cardiovascular assets, Cleviprex (clevidipine) injectable emulsion, Kengreal (cangrelor) and rights to Argatroban for Injection to Chiesi USA and its parent company Chiesi Farmaceutici. $MDCO received about $264MM in cash and has potential to receive up to $480MM in sales-based milestone payments.

$MDCO {{ '2016-06-15T16:33:20+0000' | timeago}} • Announcement

$MDCO said the Phase 2-3 development program for ABP-700 has been named VERONA by the company. The first Phase 2 study in the VERONA Program is expected to enroll 75 patients undergoing elective colonoscopies at three sites in The Netherlands. The study tests three ABP-700 infusion regimens with goal of enabling successful procedure completion.

$MDCO {{ '2016-06-15T16:32:13+0000' | timeago}} • Announcement

$MDCO said it has dosed the first patient in a Phase 2 study of ABP-700 in procedural sedation. The Phase 2 study follows within weeks of completion of Phase 1 clinical pharmacology, dosing and safety studies, including its use with pre- and co-medications routinely given as part of procedural sedation and induction of general anesthesia.

$MDCO {{ '2016-06-02T20:09:07+0000' | timeago}} • Announcement

Pharma firm $MDCO said that it has completed the patient enrollment in the ORION-1 study of PCSK9si along with its partner $ALNY. 480 patients with high cardiovascular risk and high bad cholesterol were enrolled in this study. Treatment results are anticipated by the end of 2016.

$MDCO {{ '2016-05-27T06:31:03+0000' | timeago}} • Announcement

Pharmaceutical company $MDCO said it has completed patient enrollment in Phase 3 TANGO 1 study of CARBAVANCE, an agent developed for treating complicated urinary tract infections (cUTI). TANGO 1 was initiated in 4Q14 under a cost-share agreement with BARDA to support the development of CARBAVANCE. Topline data are expected in 2H16.

$MDCO {{ '2016-05-16T11:57:29+0000' | timeago}} • Announcement

Medical solutions provider $MDCO said it has appointed Tony Kingsley, previously EVP, Global Commercial Operations at $BIIB, as COO. Kingsley will help oversee the day-to-day operations of the company and will lead the company's commercial activities.

$MDCO {{ '2016-05-09T15:42:28+0000' | timeago}} • Announcement

In addition to generating substantial non-dilutive cash, $MDCO expects the transaction and related restructuring to reduce the company's annual selling, general and administrative and related research and development expenses by between $65MM and $80MM.

$MDCO {{ '2016-05-09T15:40:53+0000' | timeago}} • Announcement

$MDCO said the total consideration of $792MM consists of $260MM in cash payable at closing, up to $480MM in sales-based milestone payments, the assumption by Chiesi of up to $50MM in milestone payment obligations and about $2MM for product inventory.

$MDCO {{ '2016-05-09T15:39:13+0000' | timeago}} • Announcement

$MDCO said it has agreed to divest non-core cardiovascular assets to Chiesi Farmaceutici. $MDCO will sell Cleviprex, Kengreal and the company's rights to Argatroban for Injection to Chiesi USA and its parent company, Chiesi Farmaceutici, for up to $792MM. The transaction is expected to close early in 3Q16.

$MDCO {{ '2016-04-11T11:55:56+0000' | timeago}} • Announcement

Healthcare company $MDCO said that the U.S. FDA has granted Fast Track Designation to the investigational agent CARBAVANCE that is used to treat urinary tract infections. CARBAVANCE is not approved for commercial use in any market and is administered as a fixed combination by IV infusion.

$MDCO {{ '2016-03-28T22:09:55+0000' | timeago}} • Announcement

Healthcare company $MDCO said investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its antithrombotic agent, KENGREAL (cangrelor) for Injection at the 65th Annual Scientific Session of the American College of Cardiology, held April 2-4, in Chicago.

Recent Transcripts

AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
ACET (Aceto Corp.)
Friday, May 5 2017 - 1:00pm
ZGNX (Zogenix, Inc.)
Thursday, May 4 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, May 3 2017 - 8:30pm
VVUS (VIVUS Inc.)
Wednesday, May 3 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, May 1 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm
XOMA (XOMA Corporation)
Thursday, March 16 2017 - 1:00pm
ZGNX (Zogenix, Inc.)
Thursday, March 9 2017 - 9:30pm
VVUS (VIVUS Inc.)
Wednesday, March 8 2017 - 9:30pm
MDCO (The Medicines Company)
Tuesday, February 28 2017 - 1:30pm
ENDP (Endo International plc)
Tuesday, February 28 2017 - 1:30pm

AlphaGraphics you may like